GSK complete $3.3bn acquisition of US vaccine developer Affinivax
GSK has completed the acquisition of US vaccine developer Affinivax in a deal worth up to $3.3bn. Completion of the … Continue reading GSK complete $3.3bn acquisition of US vaccine developer Affinivax
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
